Cantourage Group (HIGH) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
10 Nov, 2026Executive summary
Q3 2026 EBITDA rose to €1.9m from €-2.2m YoY; revenue was €19.9m vs. €20.3m, while gross margin expanded to 35.3% from 18.1%.
International markets contributed more than half of Q3 revenue, helping diversify exposure as German pricing pressure intensified.
Financial highlights
Q3 revenue €19.9m vs. €20.3m YoY; gross margin 35.3% vs. 18.1%.
Q3 EBITDA €1.9m vs. €-2.2m YoY; EBITDA margin 9.5% vs. -11.0%.
9M 2026 revenue €62.3m, EBITDA €6.8m and EBITDA margin 10.9%.
Outlook and guidance
Financial position provides flexibility to further develop the product portfolio and expand international presence.
Higher-margin products and European market diversification remain central to improving earnings quality and resilience.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cantourage Group
- Premium focus lifted Q2 EBITDA 45% YoY despite a 22% revenue decline.HIGH
Company presentation - Profitable, asset-light cannabis platform drives growth with innovation, telemedicine, and strong margins.HIGH
Company presentation - EBITDA up 45% in Q2 2026 as high-margin focus boosts profitability and international growth.HIGH
Q2 2026 - Net profit surged to €210,989.14 in H1 2024, driven by higher revenue and one-time income.HIGH
H1 2024 - Revenue and net income grew strongly, with all earnings retained and a clean audit opinion.HIGH
H2 2024 - Q1 2025 revenue soared to EUR 25.6 million, quadrupling year-over-year on robust European demand.HIGH
Q1 2025 TU - Profitable, asset-light cannabis platform drives growth with innovation and telemedicine.HIGH
Investor presentation - Revenue and profit fell, but equity and liquidity remain robust amid higher compliance costs.HIGH
H1 2025 - Q2 2025 revenue more than doubled year-over-year, exceeding last year's total annual sales.HIGH
Q2 2025 TU